Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml, for Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen (sumatriptan succinate) 6 mg/0.5 ml in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 ml is available in a carton containing 2 single-dose prefilled syringes.

The IMITREX STATdose Pen (sumatriptan succinate) brand and generic combined had US sales of approximately $169 Million MAT for the most recent twelve months ending in December 2013 according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.